Education
About Us
Working with TipRanks
Follow Us
Molecular Templates (MTEM)
OTHER OTC:MTEM
MTEM Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.01 - $1.78
Previous CloseN/A
Volume37.83K
Average Volume (3M)9.82M
Market Cap
$658.00
Enterprise Value$19.63M
Total Cash (Recent Filing)$9.66M
Total Debt (Recent Filing)$11.03M
Price to Earnings (P/E)―
Beta-214.19
Next Earnings
May 19, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.70
Shares Outstanding6,583,880
10 Day Avg. Volume250,581
30 Day Avg. Volume9,821,096
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-0.08
Price to Sales (P/S)0.00
P/FCF Ratio-0.01
Enterprise Value/Market Cap29.83K
Enterprise Value/Revenue0.12
Enterprise Value/Gross Profit1.22
Enterprise Value/Ebitda-0.54
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Molecular Templates News
PremiumCompany Announcements
Molecular Templates Announces Leadership Changes and Operational Wind Down
PremiumCompany Announcements
Molecular Templates Announces Key Leadership Transition
Options Prices
Currently, No data available
---
Ownership Overview
20.87% Insiders
0.61% Mutual Funds
<0.01% Other Institutional Investors
78.52% Public Companies and
Individual Investors
MTEM FAQ
What was Molecular Templates’s price range in the past 12 months?
Molecular Templates lowest stock price was $0.01 and its highest was $1.78 in the past 12 months.
What is Molecular Templates’s market cap?
Molecular Templates’s market cap is $658.00.
When is Molecular Templates’s upcoming earnings report date?
Molecular Templates’s upcoming earnings report date is May 19, 2025 which is 25 days ago.
How were Molecular Templates’s earnings last quarter?
Currently, no data Available
Is Molecular Templates overvalued?
According to Wall Street analysts Molecular Templates’s price is currently Overvalued.
Does Molecular Templates pay dividends?
Molecular Templates does not currently pay dividends.
What is Molecular Templates’s EPS estimate?
Molecular Templates’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Molecular Templates have?
Molecular Templates has 6,583,880 shares outstanding.
What happened to Molecular Templates’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Molecular Templates?
Currently, no hedge funds are holding shares in MTEM
Company Description
Molecular Templates
Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases. The company primarily develops a pipeline of therapies through its proprietary biologic engineered toxin body (ETB) drug platform. The company is developing MT-5111, an ETB candidate that is in Phase I clinical trial for the treatment of HER2-positive cancers; MT-0169, which is in Phase I clinical trial to treat relapsed/refractory myeloma patients; and MT-6402 in that is in Phase I clinical trial for PD-1/PD-L1 antibody relapsed/refractory patients. Its pipeline of ETBs in development for other targets, including CTLA-4, TIGIT, TROP2, BCMA, SLAMF-7, and CD45. The company has a collaboration agreement with Bristol Myers Squibb to discover and develop novel products containing ETBs directed to multiple targets. Molecular Templates, Inc. was founded in 2001 and is headquartered in Austin, Texas.
Technical Analysis
Biodexa Pharmaceuticals
―
Salarius Pharmaceuticals
―
Hepion Pharmaceuticals
―
Virpax Pharmaceuticals
―
ZyVersa Therapeutics
―